Kornimate/medical-research-clean huggingface dataset:
isometric exercises with and without pressure biofeedback in computer users with cervical spine overload

Conditions: Pain, Neck

Summary: neck pain is defined as the pain experienced from the base of the skull or occiput to the upper part of the back and extending laterally to the outer and superior bounds of the shoulder blade. office work is a kind of job that demands sitting for prolonged time requiring the use of computer. these two factors are mainly responsible for overloading of the spine. neck pain and computer users are clearly connected due to extended periods of sitting in a certain position with no breaks to stretch the neck muscles. prolonged computer use with neck bent forward will cause the anterior neck muscles to gradually get shorter and tighter, while the muscles in the back of neck will grow longer and weaker. these changes will lead to development of neck pain. neck problem also accounts for a large proportion of occupational illness and disability. neck pain is common among computer workers in our country and contributes importantly to the demand for medical services and the economic burden of absence from work due to sickness. the main purpose of this randomized clinical trial will be to find out the effects of isometric exercises with and without pressure biofeedback unit on cervical pain and muscle strength in computer users with cervical spine overload. patients will be recruited in the study by convenient sampling technique after that will be allocated to groups by simple random assignment with an inclusion criteria having chronic neck pain for more than 3 months, current pain level ranging greater than 3 on nprs, patient with minimum and moderate disability and male and female computer users with age 25 to 40 years with cervical pain. patients with history of cervical trauma, postural deformity, spinal cord deformity, current pregnancy and significant neurological deficits were excluded. numeric pain rating scale (nprs) and neck disability index (ndi) will be used to measure before and after treatment session. treatment will be given to both groups for 4 weeks and each group will receive 3 sessions per week. after collecting the data it will entered and analysed using statistical package for the social sciences (spss) version 25. data will be assessed by using parametric/ non parametric test after completion of the study.


Eligibility criteria:
inclusion criteria: * aged between 20-40 years among male and female with cervical pain * having chronic pain for more than 3 months. * current pain level ranging greater than 3 on nprs * patients with minimum and moderate disability based on ndi exclusion criteria: * history of cervical trauma * postural deformity * spinal cord deformity ( scoliosis, kyphosis, lordosis) * current pregnancy * significant neurological deficits ( cervical radiculopathy, cervical spondylosis)
conventional low flow oxygenation versus high flow nasal cannula in hypercapnic respiratory failure

Conditions: Hypercapnic Respiratory Failure; Acute Copd Exacerbation

Summary: current evidence suggests a mechanistic and physiological rationale for the use of high flow nasal cannula (hfnc) in acute respiratory hypoxemic failure (ahrf) based on physiological studies in airway models, healthy volunteers and patients with chronic obstructive respiratory disease (copd). this is supported by observational studies in patients with ahrf with reductions in a range of respiratory and other physiological parameters. observational studies also suggest similar intubation rates and lower failure rates with hfnc when compared to non-invasive ventilation (niv) with improved patient acceptance and tolerance for hfnc. the role of hfnc is less clear in acute hypercapnic respiratory failure. although non-invasive ventilation is the recommended treatment, it is associated with discomfort, and a significant proportion (up to 25% in some reports) cannot tolerate non-invasive ventilation. observational reports and limited data from randomized controlled trials suggests that hfnc is effective in treating patients with hypercapnic respiratory failure. we designed this trial to assess whether early application of hfnc in patients with non-severe hypercapnic respiratory failure can correct barometric abnormalities, and prevent progression to non-invasive ventilation or tracheal intubation and mechanical ventilation.


Eligibility criteria:
inclusion criteria: * adult patients \> 18 years of age * acute hypercapnic respiratory failure with ph \ 45 mmhg exclusion criteria: * pregnant or breast-feeding * patients who cannot read and understand french or english * hypercapnia secondary to a drug toxicity or non-pulmonary aetiology * hypercapnia secondary to exacerbation of asthma * contraindication to niv * contraindication to hfnc * not for escalation to niv based on a ceiling of care * ph \< 7.15 * gcs 8 or less * shock defined as systolic \< 90 mmhg or a reduction by 20mmhg from usual systolic bp despite volume resuscitation * respiratory or cardio-respiratory arrest * any other indication that requires immediate invasive/non-invasive mechanical ventilation

Keywords: high flow nasal cannula high flow nasal insufflation high flow oxygen therapy high flow oxygenation
efficacy and safety of rtx-grt7039 in adult subjects with knee osteoarthritis

Conditions: Osteoarthritis

Summary: a double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated injections of rtx-grt7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.

this trial comprises a total observation period of up to 52 weeks.

Eligibility criteria:
inclusion criteria: * the participant has given written informed consent to participate. * the participant is 18 years of age or older at the screening visit. * the participant has a diagnosis of osteoarthritis of the knee based on american college of rheumatology criteria and functional capacity class of i to iii. * there is a documented history indicating that participant has insufficient pain relief with previous standard of care. exclusion criteria: * the participant has past joint replacement surgery of the index knee. * the participant has a history of significant trauma or surgery (e.g., open or arthroscopic) to the index knee within 12 months of screening. * the participant has periarticular pain from any cause other than osteoarthritis, including referred pain, bursitis, or tendonitis. * the participant has clinical hip osteoarthritis on the side of the index knee. * the participant has pre-existing osteonecrosis, subchondral insufficiency fracture, atrophic osteoarthritis, severe bone on bone osteoarthritis, knee pain attributable to disease other than osteoarthritis, or the participant has rapidly progressing osteoarthritis (rpoa) type i or type ii. * the participant has significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the target knee (varus \>10, valgus \>10) by x-ray as assessed by independent central readers at screening visit. * the participant has other conditions that could affect trial endpoint assessments of the index knee. * the participant has current clinically significant disease(s) or condition(s) that may affect efficacy or safety assessments, or any other reason which, in the investigator's opinion, may preclude the participant's participation for the full duration of the trial. * the participant has a history of hypersensitivity to resiniferatoxin (rtx) or any similar component (capsaicin, chili peppers). * the participant is currently participating or was participating in another investigational drug trial within 3 months prior to the screening visit. * the participant is an employee of the investigator or trial site, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial site or is a family member of the employees or the investigator.

Keywords: knee, osteoarthritis pain assessment
gather mhealth india rct for behavior and health outcomes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this trial is to explore the impact of the gather health diabetes management platform diabetics' health behaviors and health outcomes and how providers and diabetics interact with the gather health platform.

the overall aim of the study is to estimate the impact of the gather health diabetes management platform on hba1c, glycemic control, patient behavior, and physical and psychosocial measures. additionally, this study will investigate patient and provider satisfaction with the platform. primary objective: estimate the impact of the gather health diabetes management platform on hba1c among diabetics in 3 cities in india. secondary objective: 1. estimate the impact of the gather health diabetes management platform on medication adherence, blood glucose (bg) control, body mass index (bmi), blood pressure (bp), and other behavior and health measures among diabetics in 3 cities in india. 2. estimate patient and provider's satisfaction with the platform and the perceived usability and time spent on the platform 3. generate ideas for future changes to the platform to make it more effective and user-friendly

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus, diagnosis for \> 6 months. * age 18-65, participants of either gender- males or females. * hba1c between 7.5% and 12.5% within last 6 months (inclusive). * on stable diabetes therapy for \>3 months prior to enrollment. * own an android smartphone. * participant willing to sign and date written informed consent form to participate in the study. * willing to comply with the study schedule and procedures including randomization. exclusion criteria: * previously used gather health * currently using an insulin pump or continuous glucose monitor. * pregnant or planning to become pregnant in the next 12 months. * severe hearing or visual impairment. * active substance, alcohol, or drug abuser (sober \<1 year). * any psychiatric illness including psychosis or schizophrenia that will impair the patient's ability to complete the study or follow study protocol. * recent major surgery or planning to have major surgery * significant renal, hepatic, or other disease that may impair patient's ability to complete the study or follow study protocol * using glucocorticoids * patients who have received or are planning to receive an organ transplant

Keywords: mhealth telemedicine randomized controlled trial glucose control
study to assess safety, tolerability and efficacy of intravenous cabaletta in patients with machado-joseph disease

Conditions: Machado-Joseph Disease / Spinocerebellar Ataxia 3

Summary: * this is an exploratory, randomized, parallel-group, dose escalation and dose-controlled study without a placebo arm. * eligible patients will be randomized in a 1:1 ratio (double-blind) to receive cabaletta in 2 doses, once weekly for 22 weeks (total of 24 weeks of treatment).


Eligibility criteria:
inclusion criteria: 1. men and women, 18 - 75 years 2. clinically diagnosed as machado-joseph disease/spinocerebellar ataxia 3 confirmed by genetic testing 3. with disease stage 2 or less 4. stable doses of all medications for 30 days prior to study entry and for the duration of the study. 5. body mass index (bmi) ≤32 kg/m2. 6. ability to ambulate with or without assistance exclusion criteria: 1. diabetes mellitus type 1 or 2 2. other major diseases 3. uncontrolled heart disease, chronic heart failure (chf). 4. other neurological diseases. 5. ataxia derived from any other cause than genetically-confirmed spinocerebellar ataxia 6. presence of psychosis, bipolar disorder, untreated depression 7. history of malignancy (except non-invasive skin malignancy).

Keywords: bioblast, randomized, parallel-group, and dose-controlled
auditory beat stimulation and behavioural variant of frontotemporal dementia

Conditions: Anxiety; bvFTD

Summary: the goal of this study is to examine the effects of auditory beat stimulation on anxiety in patients diagnosed with bvftd. main aims are: * to ascertain whether anxiety in bvftd patients can be modulated using auditory beat stimulation * to investigate patterns of anxiety and mind wandering in bvftd patient population patients were asked to complete a number of questionnaires relating to well-being and mind wandering, as well as to listen daily to audio files of beat stimulation.

eligible patients and their caregivers were asked to give informed written consent, if they wished to participate after an initial interview. once enrolled, they began the study by joining a consultation with their consultant neurologist and the study coordinator. patients each received a handbook to guide them day by day during the course of the study and an mp3 player containing the auditory beat stimulation files. the handbook also contained copies of the questionnaires the patients were asked to complete at different points during the two week study (mind wandering questionnaire, state-trait anxiety inventory, beck depression inventory, rogers' happy/ sad face scale). over the course of two weeks patients completed the questionnaires and listened daily to an auditory beat stimulation or a control recording for 20 mins at home.

Eligibility criteria:
inclusion criteria: * inclusion criteria are the international criteria of a behavioral variant of ftd according to raskovsky and colleagues (2011), which include: a. early disinhibition b. early apathy or passivity c. early loss of compassion or empathy d. speech or motor stereotypies e. hyperorality and altered eating habits f. neuropsychological profile with executive function deficits with relatively unchanged memory and visuospatial performance g. disruption of daily living skills h. matching imaging (cmri, cct, pet). exclusion criteria: * exclusion criteria include the presence of a non-neurodegenerative psychiatric disease that can better explain the behavioral abnormalities or evidence of biomarkers with clear evidence of alzheimer's disease or other neurodegenerative process
the effects of a 12 week home-based exercise intervention on physical performance in patients with cancers of the gastrointestinal tract with pre- cachexia or cachexia

Conditions: Cachexia; Weight Loss; Gastrointestinal Cancer

Summary: the main purpose of this research study is to determine if exercise improve or worsen cachexia.

in this study the investigator would like to better understand how cachexia may improve or worsen, and how exercise may impact this process. the investigator would like to see whether a progressive resistance exercise program (excap©®, exercise for cancer patients) can improve symptoms in patients with gastrointestinal cancers with weight loss and cachexia. the investigator would also like to find out if this exercise intervention improves physical performance, day-to-day function, quality of life, and how exercise may affect different markers in the blood over time.

Eligibility criteria:
inclusion criteria: * have a primary diagnosis of colorectal, esophageal, gastric, pancreatic or biliary tract cancer and plans to initiate systemic chemotherapy within the next 4 weeks after enrollment. * have been diagnosed as having an advanced unresectable cancer with no plans for surgical intervention during the active study period (12 weeks). * have an ecog performance score of 0 or 1. * have a life expectancy of \>3 months as determined by their primary oncologist. * have experienced at least 2% weight loss of the patient's reported previous body weight over the 6 months prior to enrollment. patients who have 2 - 4.9% weight loss should also have one of the following metabolic changes: a hemoglobin level \ 5.7, a random glucose level \>200 or a fasting glucose level \>100. * have permission from primary oncologist to engage in low to moderate intensity exercise regimen. * be able to read english (since the assessment materials are in printed format). * be able to give written informed consent. exclusion criteria: * have any of the following limitations: unable to walk the 4 meters of the sppb test, wheel-chair bound, unable to perform low-to-moderate intensity exercise regimen (patients unable to perform 6 minute walk or stair climb test will be allowed to participate, but will be held out of these measurements). * have had major surgery (excluding diagnostic procedures like laparoscopy, egd/eus, esophageal stent placement) in the past 4 weeks. * be experiencing dysphagia that requires enteral or parenteral feeding for nutrition. * be enrolled on hospice at time of consent. * be engaged in an active exercise routine by being identified as in the active or maintenance stage of exercise behavior as assessed by the 1-item exercise stages of change short form (40).

Keywords: cachexia weight loss exercise gastrointestinal cancer
prospective urban rural epidemiology study

Conditions: Cardiovascular Diseases; Risk Factor, Cardiovascular; Health Behavior; Environmental Exposure; Lung Diseases; Cancer; Injuries; Renal Disease; Communicable Disease

Summary: to examine the impact of health determinants at the individual (e.g. health related behaviors) and societal level (e.g. environmental factors, health related policy, quality of health systems) on health outcomes (e.g. death, non-communicable disease development) across a range of socioeconomic and health resource settings. additional components of this study will examine genetic factors for non-communicable diseases. this will be examined both through a cross sectional component, and prospectively (cohort component).

1. to examine the relationship between societal influences and prevalence of risk factors and chronic noncommunicable diseases. societal determinants are measured by an index of measures from each of the 4 domains of interest: built environment, food and nutrition policy, psychosocial/socioeconomic factors, and tobacco. 2. to examine the relationship between societal determinants and incidence of chronic noncommunicable disease events (e.g. cardiovascular disease, cancer) and on changes in rates of selected risk factors (e.g. smoking) 3. to examine the relationship between health related behaviors (e.g. diet, physical activity, smoking, alcohol) and health outcomes (e.g. death, non-communicable diseases) 4. the quality of health systems across a diverse range of health resource settings, and how this impacts health outcomes 5. genetic factors for non-communicable diseases

Eligibility criteria:
inclusion criteria: * consenting adults between 35-70 years of age exclusion criteria: * none

Keywords: non-communicable diseases, risk factors
tart cherry and omega-3's for aromatase inhibitor musculoskeletal symptoms

Conditions: Breast Cancer; Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS); Joint Pain

Summary: both tart cherry and omega 3 fas have better side effect profiles compared to other commonly used medications for aimss, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. additionally, in our clinics we often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. further, both tart cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addition to other health issues like insomnia. there is preliminary evidence in mouse models that when given together, these supplements may have an even greater anti-inflammatory effect than when taken separately14. although to our knowledge, no human studies have tested this hypothesis. this study has been designed to test the hypothesis that tart cherry and fish oil when given in combination over a 12-week period could produce beneficial changes in joint function when compared to tart cherry or fish oil in isolation in an obese breast cancer population experiencing aimss. secondary outcomes to be assessed include pain, functional performance, quality of life and cognition.


Eligibility criteria:
inclusion criteria: * breast cancer diagnosis (stage i-iii) with any hormonal status. * females aged ≥ 18 years. * currently receiving ai therapy. * bmi ≥ 27. * clinical diagnosis of aimss. * omega-3 index \&lt;8%. * average joint pain score ≥ 4 on the brief pain inventory (bpi) within 7 days of enrollment. * written informed consent obtained from subject and ability and willingness of subject to comply with the requirements of the study. exclusion criteria: * current use of anticoagulant medications (including but not limited to warfarin, lovenox, eliquis, xarelto). * allergy to cherries or fish/fish products. * lifetime history of rheumatoid arthritis and/or inflammatory joint diseases (including but not limited to reactive arthritis, ankylosing spondylitis, and psoriatic arthritis). * uncontrolled diabetes mellitus as determined by treating physician (with or without the use of glucose lowering medications and/or insulin). * lifetime history of stroke or transient ischemic attacks. * new use or dose change of oral or topical analgesics in the previous 14 days. (including but not limited to opioids, non-steroidal anti-inflammatories, acetaminophen, snri's, ssri's, gabapentinoids, tricyclic antidepressants, and muscle relaxants). * oral or intra-articular steroid use in the previous 30 days (including but not limited to dexamethasone, prednisone, methylprednisolone, triamcinolone, hydrocortisone). * history of joint fracture or surgery of the symptomatic joint in the previous 6 months.

Keywords: aromatase inhibitor therapy aimss aromatase inhibitor associated musculoskeletal symptoms (aimss) tart cherry omega 3 fatty acids fish oil female breast cancer aromatase inhibitor arthralgia
cytoreductive prostatectomy versus cytoreductive prostate irradiation as a local treatment option for metastatic prostate cancer: a multicentric feasibility trial

Conditions: Prostate Cancer Metastatic

Summary: according to the guidelines of the european association of urology (eau), the first-line treatment for newly diagnosed mpc consists of immediate castration with the addition of docetaxel or abiraterone acetate. as seen in other well-known solid tumours - such as ovarian, colon and renal cancer - local treatment (lt) of the primary tumour could lead to a survival benefit compared to standard of care (soc). several retrospective studies have suggested a survival benefit of local treatment of the primary tumour with soc versus soc only in mpc. these patients also have less local symptoms of their disease, which has a major impact on quality of life (qol). several prospective studies have already been set up to compare either surgery or radiotherapy with the soc. in expectation of their results and because randomization seems challenging, the investigators want to set up a trial to evaluate the feasibility of randomization between both local treatment groups.


Eligibility criteria:
inclusion criteria: * male ≥18y * histologically proven pc * newly diagnosed metastatic pc as assessed by standard imaging (ct and bone scintigraphy) or psma pet-ct * ecog 0-1 (2 if related to local pc symptoms) * eligible for local treatment * written informed consent and able and willing to comply with protocol requirements exclusion criteria: * previous systemic treatment for pc except adt started within 3 months before randomization * previous radiotherapy to the pelvis interfering with prostate irradiation * previous surgery in the pelvis interfering with radical prostatectomy * symptoms related to metastatic lesions, persisting for at least 2 weeks after initiation of adt * metastatic brain disease, leptomeningeal disease or imminent spinal cord compression * previous or current malignant disease which is likely to interfere with lomp ii treatment or assessment * psychological disorder intervening with understanding the information or the informed consent

Keywords: metastatic prostate cancer local cytoreductive